|
Q3 FY2026
As of Sep 30, 2026
|
Q2 FY2026
As of Jun 30, 2026
|
Q1 FY2026
As of Mar 31, 2026
|
Q4 FY2025
As of Dec 31, 2025
|
Q3 FY2025
As of Sep 30, 2025
|
Q2 FY2025
As of Jun 30, 2025
|
Q1 FY2025
As of Mar 31, 2025
|
Q4 FY2024
As of Dec 31, 2024
|
Q3 FY2024
As of Sep 30, 2024
|
Q2 FY2024
As of Jun 30, 2024
|
Q1 FY2024
As of Mar 31, 2024
|
Q4 FY2023
As of Dec 31, 2023
|
Q3 FY2023
As of Sep 30, 2023
|
Q2 FY2023
As of Jun 30, 2023
|
Q1 FY2023
As of Mar 31, 2023
|
Q4 FY2022
As of Dec 31, 2022
|
Q3 FY2022
As of Sep 30, 2022
|
Q2 FY2022
As of Jun 30, 2022
|
Q1 FY2022
As of Mar 31, 2022
|
Q4 FY2021
As of Dec 31, 2021
|
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||||||||||||||
| Current Assets | ||||||||||||||||||||
| Cash and cash equivalents | ||||||||||||||||||||
| Inventories | ||||||||||||||||||||
| Deferred clinical supply costs | ||||||||||||||||||||
| License fee and expense reimbursements receivable | ||||||||||||||||||||
| Deposit to be refunded | ||||||||||||||||||||
| Stablecoins | ||||||||||||||||||||
| Prepaid expenses and other current assets | ||||||||||||||||||||
| Total Current Assets | ||||||||||||||||||||
| Intangible assets | ||||||||||||||||||||
| Prepaid expenses, non-current | ||||||||||||||||||||
| Digital assets | ||||||||||||||||||||
| Property and equipment, net | ||||||||||||||||||||
| Deferred offering costs | ||||||||||||||||||||
| Security deposits, non-current | ||||||||||||||||||||
| Digital assets receivable, net | ||||||||||||||||||||
| Digital intangible assets | ||||||||||||||||||||
| Digital intangible assets receivable, net | ||||||||||||||||||||
| Operating lease right-of-use asset | ||||||||||||||||||||
| Equipment deposits | ||||||||||||||||||||
| Other assets | ||||||||||||||||||||
| Total Assets | ||||||||||||||||||||
| Liabilities and Stockholders' Equity | ||||||||||||||||||||
| Current Liabilities: | ||||||||||||||||||||
| Accounts payable | ||||||||||||||||||||
| Accrued compensation | ||||||||||||||||||||
| Accrued inducement grant | ||||||||||||||||||||
| Accrued former licensor obligations | ||||||||||||||||||||
| Accrued expenses and other current liabilities | ||||||||||||||||||||
| Deferred revenue - current portion | ||||||||||||||||||||
| Operating lease liabilities - current portion | ||||||||||||||||||||
| Note payable - current portion, net | ||||||||||||||||||||
| Convertible notes payable - net of debt discount of $0 and $263,930 as of December 31, 2025 and December 31, 2024, respectively | ||||||||||||||||||||
| Total Current Liabilities | ||||||||||||||||||||
| Notes payable - non-current portion, net | ||||||||||||||||||||
| Accrued expenses and other non-current liabilities | ||||||||||||||||||||
| Note payable - non-current portion, net | ||||||||||||||||||||
| Convertible notes payable - non-current portion, net of debt discount of $0 and $398,569 as of December 31, 2024 and 2023, respectively | ||||||||||||||||||||
| Operating lease liabilities, non-current portion | ||||||||||||||||||||
| Total Liabilities | ||||||||||||||||||||
| Stockholders' Equity | ||||||||||||||||||||
| Preferred stock, $0.0001 par value, 60,000,000 shares authorized; Series A Non-Voting Convertible Preferred Stock, 5,435,898 shares designated; 5,235,897 and 5,435,897 shares issued and outstanding as of September 30, 2026 and December 31, 2025, respectively with a liquidation preference of $50,766,000 as of September 30, 2026 | ||||||||||||||||||||
| Common stock, $0.0001 par value, 600,000,000 shares authorized; 7,162,659 and 1,506,369 shares issued and outstanding as of September 30, 2025 and December 31, 2024, respectively | ||||||||||||||||||||
| Common stock, $0.0001 par value, 600,000,000 shares authorized; 15,442,482 shares issued and outstanding as of September 30, 2026; 8,762,329 shares issued and 8,680,005 shares outstanding as of December 31, 2025, respectively | ||||||||||||||||||||
| Additional paid-in-capital | ||||||||||||||||||||
| Treasury stock, at cost, 0 and 82,324 shares as of September 30, 2026 and December 31, 2025, respectively | ||||||||||||||||||||
| Accumulated deficit | ||||||||||||||||||||
| Total Stockholders' Equity | ||||||||||||||||||||
| Total Liabilities and Stockholders' Equity | ||||||||||||||||||||
Loading...